Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
237 Leser
Artikel bewerten:
(0)

EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Neurotrope, Inc. and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / June 26, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Neurotrope, Inc. ("Neurotrope" or the "Company") (NASDAQ: NTRP). Investors, who purchased or otherwise acquired Neurotrope shares from January 7, 2016 through April 28, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the July 17, 2017 lead plaintiff motion deadline.

If you purchased Neurotrope shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, Neurotrope made false and/or misleading statements and/or failed to disclose material adverse information about the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, the Company announced "positive top-line results" of the focal Phase 2b trials of Bryostatin-1, mentioning "improvement in patients with moderate to severe Alzheimer's disease." The trial data negates these statements, however, as the top-line data relating to the 20-microgram dose of Bryostatin-1 did not produce statistically significant results. Neurotrope also allegedly failed to disclose statements about the efficacy of the 40-microgram dose in connection with its primary and secondary endpoints. After release of this news, the stock price of Neurotrope fell materially, which harmed investors according to the Complaint.

If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may be considered Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2017 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.